Deliveries to the European countries of the vaccine developed by AstraZeneca / Oxford, pending approval, will be lower than expected due to a “drop in performance” at one of the manufacturing plants, the British group said on Friday.
The European Medicines Agency (EMA) announced on 12 January that it had received an application for authorization for the COVID-19 vaccine developed by the British laboratory AstraZeneca and the University of Oxford and said it could make its decision on January 29.
Following the British announcement on Friday, a spokesman for the European Commission simply stated that they are “working to get more information.”
A spokeswoman for AstraZeneca explained to AFP that “although there is no set deadline for the start of shipments of the vaccine, if it receives approval in Europe, the initial volumes will be lower than originally planned due to a drop in yield by one year. manufacturing center of our European supply chain. “
“We will supply tens of millions of doses in February and March to the European Union, and we continue to increase production volumes,” he added, without specifying exact quantities.
The European Union and the EMA are under strong pressure from member countries to accelerate the approval of new coronavirus vaccines. The vaccine AstraZeneca/Oxford it has the advantage of being cheaper to produce than its rivals.
It is also easier to store and transport, especially compared to the one developed by Pfizer / BioNTech, which must be stored at very low temperatures (-70 ° C).
Newsletter All about the coronavirus
COVID-19 has put everyone on alert. Subscribe to our newsletter All about the coronavirus, where you will find the most relevant daily data in the country and the world on the progress of the virus and the fight against its spread.
– ‘Espacio Vital’: What is pandemic fatigue and how to avoid it? Dr. Elmer Huerta responds: